PANOVA-3: Pivotal randomized open-label study of Tumor Treating Fields (TTFields 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma

Brief description of study

To test the efficacy and safety of gemcitabine and nab-paclitaxel, with or without TTFields, using the NovoTTF-100L(P) System as a front-line therapy for locally-advanced pancreatic adenocarcinoma patients

Clinical Study Identifier: s17-01038 Identifier: NCT03377491
Principal Investigator: Francis Arena.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.